The Manufacturers Life Insurance Company Trims Stake in Immunome, Inc. $IMNM

The Manufacturers Life Insurance Company cut its stake in Immunome, Inc. (NASDAQ:IMNM) by 12.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 206,799 shares of the company’s stock after selling 30,471 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.18% of Immunome worth $4,523,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Immunome by 23.4% in the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the period. Nan Fung Trinity HK Ltd. increased its holdings in Immunome by 20.7% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock valued at $15,349,000 after buying an additional 122,450 shares in the last quarter. Profund Advisors LLC increased its holdings in Immunome by 121.7% in the fourth quarter. Profund Advisors LLC now owns 42,700 shares of the company’s stock valued at $917,000 after buying an additional 23,440 shares in the last quarter. Maven Securities LTD acquired a new position in shares of Immunome in the fourth quarter worth about $1,611,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Immunome in the fourth quarter worth about $3,652,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

IMNM has been the subject of a number of recent analyst reports. Leerink Partners cut their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Barclays initiated coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, HC Wainwright reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and an average price target of $34.18.

Insider Activity at Immunome

In other news, Director Isaac Barchas sold 16,906 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $24.20, for a total value of $409,125.20. Following the transaction, the director directly owned 108,504 shares of the company’s stock, valued at approximately $2,625,796.80. This trade represents a 13.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total transaction of $2,273,555.44. Following the transaction, the insider owned 50,366 shares in the company, valued at $1,263,682.94. The trade was a 64.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 562,758 shares of company stock worth $12,536,203 over the last 90 days. Corporate insiders own 7.21% of the company’s stock.

Immunome Price Performance

NASDAQ IMNM opened at $25.82 on Friday. The stock’s 50 day simple moving average is $21.43 and its 200-day simple moving average is $22.14. The company has a market cap of $2.92 billion, a PE ratio of -10.85 and a beta of 2.08. Immunome, Inc. has a 1-year low of $8.66 and a 1-year high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, equities research analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.